Format

Send to

Choose Destination
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268. doi: 10.1007/s00259-017-3711-7. Epub 2017 May 12.

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Author information

1
Department of Nuclear Medicine, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany. a.afshar@gmx.de.
2
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Centre, Heidelberg, Germany. a.afshar@gmx.de.
3
Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
4
Department of Nuclear Medicine, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany.
5
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Centre, Heidelberg, Germany.
6
Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany.
7
Department of Urology, Heidelberg University Hospital, Heidelberg, Germany.
8
Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany.
9
Department of Radiation Oncology and Therapy, Heidelberg University Hospital, Heidelberg, Germany.

Abstract

PURPOSE:

Since the clinical introduction of 68Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the influence of several variables with possible influence on PSMA ligand uptake in a large cohort.

METHODS:

We performed a retrospective analysis of 1007 consecutive patients who were scanned with 68Ga-PSMA-11 PET/CT (1 h after injection) from January 2014 to January 2017 to detect recurrent disease. Patients with untreated primary PCa or patients referred for PSMA radioligand therapy were excluded. The possible effects of different variables including PSA level and PSA doubling time (PSADT), PSA velocity (PSAVel), Gleason score (GSC, including separate analysis of GSC 7a and 7b), ongoing androgen deprivation therapy (ADT), patient age and amount of injected activity were evaluated.

RESULTS:

In 79.5% of patients at least one lesion with characteristics suggestive of recurrent PCa was detected. A pathological (positive) PET/CT scan was associated with PSA level and ADT. GSC, amount of injected activity, patient age, PSADT and PSAVel were not associated with a positive PET/CT scan in multivariate analysis.

CONCLUSION:

68Ga-PSMA-11 PET/CT detects tumour lesions in a high percentage of patients with recurrent PCa. Tumour detection is clearly associated with PSA level and ADT. Only a tendency for an association without statistical significance was found between higher GSC and a higher probability of a pathological PET/CT scan. No associations were found between a pathological 68Ga-PSMA-11 PET/CT scan and patient age, amount of injected activity, PSADT or PSAVel.

KEYWORDS:

PET/CT; PSMA; Positron emission tomography; Prostate cancer; Prostate-specific membrane antigen

PMID:
28497198
PMCID:
PMC5486817
DOI:
10.1007/s00259-017-3711-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center